Imagine a surgeon wearing smart glasses that highlight a tumor in bright colors, like a highlighter pen on a page, right while they are operating. Instead of looking away at a bulky monitor and guessing where the tumor is, the markers appear directly on the patient's body. This makes the surgery faster and helps ensure no cancer cells are left behind.
Surgeons currently rely on bulky towers and external screens to see fluorescent markers, forcing them to subjectively map a 2D screen to a 3D body. This leads to higher tumor recurrence rates and inefficient operating room workflows.
A wearable AR headset with integrated NIR sensors and computer vision algorithms that project tumor margins directly onto the surgical field.
If you are a hospital dealing with high tumor recurrence rates and long operating times — this project developed AR glasses that visualize biomarkers in the surgeon's direct sight. This increases resection precision and reduces the time spent on each procedure.
If you are a device manufacturer dealing with the inefficiency of bulky camera towers and external screens — this project developed a wearable NIR sensor system. It replaces heavy hardware with lightweight glasses, lowering running costs and improving accessibility.
If you are a clinic dealing with the difficulty of mapping monitor images to real anatomy — this project developed a hands-free NIR visualization tool. This allows for more accurate identification of critical structures during complex reconstructive procedures.
Based on available project data, the technology aims to democratize access by reducing hardware costs and lowering running costs compared to bulky camera towers.
Based on available project data, the technology is not yet commercially available and is currently in the process of validation for MDR CE and FDA certification.
Based on available project data, the project is coordinated by ARSPECTRA S.A.R.L., but specific licensing terms are not disclosed.
The system must undergo validation to achieve MDR CE and FDA certification before it can be sold on the market.
It replaces external monitors and bulky towers with a wearable AR headset, providing a hands-free, real-time visualization in the surgeon's line of sight.
The project is led by a single SME, ARSPECTRA S.A.R.L. from Luxembourg, representing a 100% industry ratio. This lean structure suggests a highly focused commercial drive, though it lacks the academic research partners typically seen in early-stage EU consortia, indicating the technology is moving toward commercialization.
Contact ARSPECTRA S.A.R.L. in Luxembourg
Contact us to find partners for clinical validation trials.
